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Abstract.  Bovine aortic endothelial cells (BAEs) were 
used as a model system to study the nature and origin 
of protein(s)  in the extracellular matrix that bind to 
type 1 plasminogen activator inhibitor (PAl-I).  Matrix 
samples were fractionated by SDS-PAGE and analyzed 
by PAI-1 ligand binding and by immunoblotting using 
antibodies to vitronectin (Vn).  PAI-1 bound primarily 
to two Vn-related polypeptides of Mr 63,000 and 
57,000, and both of these partially degraded polypep- 
tides were present in the culture serum.  Radiolabeling 
experiments failed to detect significant Vn biosynthesis 
by BAEs (<0.03 % of total),  or by human umbilical 
vein endothelial cells and HT 1080 ceils.  The binding 
of PAId to Vn was relatively specific since direct 
binding studies failed to demonstrate significant inter- 
actions between PAId and other matrix proteins (e.g., 
fibronectin,  type IV collagen, laminin,  or matrigel). 
Kinetic studies indicate that PAId  rapidly accumulates 
in the matrix when BAEs are plated on Vn,  appearing 
in the conditioned medium only after a  significant lag 
period (1-2 h).  However, no PAI-1 was detected in the 
matrix when the cells were plated on fibronectin- 
coated dishes, and there was no lag period for PAI-1 
accumulation in the medium.  These results indicate 
that PAId binds specifically to serum-derived Vn in 
the matrix,  and suggest that the composition of both 
the matrix and serum itself may influence the pericel- 
lular distribution of this important  inhibitor. 
T 
ar~ extracellular  matrix  (ECM) ~ of cultured cells is 
composed of a fibrillar  network of proteoglycans  and 
glycoproteins  such  as  fibronectin  (Fn),  vitronectin 
(Vn),  collagen,  elastin,  and  laminln  (Alitalo  and Vaheri, 
1982; Hayman et al., 1983). The ECM mediates the attach- 
ment of cells to their substratum and participates  in the regu- 
lation of cell differentiation,  proliferation,  and morphogene- 
sis  (Kleinman  et al.,  1981). The  fibrinolytic  system  can 
proteolytically  modify the  structure  and  function  of the 
ECM  (Dano  et al.,  1985).  This  degradation  is mediated 
largely by plasmin,  a proteolytic enzyme capable of degrad- 
ing most glycoprotein components of the matrix (Dano et al., 
1985; Saksela,  1985; Saksela and Rifkin, 1988). Plasmin is 
formed from the  abundant  extraceUular  proenzyme plas- 
minogen through the action of plasminogen  activators (PAs). 
Thus,  regulation  of PA activity is a key step in controlling 
biological events occurring in the ECM. 
Specific  PA inhibitors  (PAls) appear to be the primary 
regulators of PA activity  (Loskutoff et al.,  1989).  One of 
these,  type 1 PAl (PAl-l),  has been detected in the ECM of 
a number of cultured cells (Laiho et al., 1986; Rheinwald et 
al.,  1987; Knudsen et al.,  1987) including  bovine (Mimuro 
et  al.,  1987)  and  human  (Levin  and  Santell,  1987)  en- 
1. Abbreviations used in this paper:  BAE,  bovine aortic endothelial cell; 
CM,  conditioned medium;  ECM,  extracellular matrix; Fn,  fibronectin; 
HUVEC, human umbilical vein endothelial cell; PA, plasminogen activa- 
tor; PAl, PA inhibitor; PAl-I, type 1 PAl; t-PA, tissue-type plasminogen ac- 
tivator; Vn, vitronectin; u-PA, urokinase-type plasminogen activator. 
dothelial cells. Although the majority of PAl-1 in conditioned 
mediurii (CM) is inactive  (Hekman and Loskutoff, 1985), 
the PAl-1 present in the ECM appears to be fully active since 
it binds to and inhibits both tissue-type PA (t-PA; Knudsen 
et al., 1987; Levin and Santell,  1987; Mimuro et al., 1987) 
and urinary-type PA (u-PA; Knudsen  et al.,  1987; Laiho et 
al., 1987). The binding of PAl-1 to ECM protects it from the 
spontaneous loss of activity that occurs in solution after it 
is secreted (Mimuro et al.,  1987; Mimuro and Loskutoff, 
1989b).  Kinetic data suggest that PAl-1 may be secreted in 
a polar manner since it is detected in the ECM immediately 
after secretion but appears in the CM only after a lag period 
(Rheinwald et al., 1987; Laiho et al., 1987). It has been sug- 
gested that active, matrix-associated  PAI-1 may protect ECM 
proteins against cellular  proteases and thus play a role in a 
variety of biological processes (Dano et al.,  1985; Saksela 
and Rifldn,  1988). 
Although  the identity  of the PAl-1 binding  protein(s)  in 
ECM  is  unknown,  a  PAI-1 binding  protein  recently  was 
purified  from human (Declerk et al.,  1988; Wiman et al., 
1988) and bovine (Mimuro and Loskutoff, 1989a)  plasma 
and shown to be the adhesive glycoprotein Vn. Purified Vn 
competes with ECM for binding  to PAl-l,  suggesting  that 
PAl-1 in ECM is bound, at least in part, to Vn (Mimuro et 
al., 1989a).  The relative affinities of PAI-1 for other matrix 
proteins  are unknown. 
In this report, we investigate the role of Vn and other ECM 
proteins on the binding  and concentration of PAI-1 on the 
culture substratum.  We show that while Vn is indeed the ma- 
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aortic endothelial  cells (BAEs), it is not synthesized  by the 
cells  but  rather derived  from  the  tissue  culture  serum. 
Moreover,  BAEs plated  on fibronectin,  type IV collagen, 
laminin,  and matrigel deposited little PAL1 into ECM, sug- 
gesting that the composition of the ECM itself affects the ac- 
tual pericellular  distribution  of PAI-1. 
Materials and Methods 
All chemicals were the highest analytical grade commercially  available. 
Tissue  culture  materials  were  purchased  from  the  following  sources: 
Plasticware from Coming Glass Works, Coming Scientific Products (Corn- 
ing, NY); MEM, and methionine-free MEM from Irvine Scientific (Santa 
Ana, CA); Medium 199 from M. A. Bioproducts (Bethesda, MD); F12 and 
DME from Whittaker Bioproducts  (Walkersville,  MD); calf serum, FCS, 
trypsin, penicillin, and streptomycin  from Gibco Laboratories (Grand Is- 
land, NY); endothelial cell growth factor from Biomedical  Technologies, 
Inc.  (Stoughton, MA). Other biologicais  were obtained as follows: BSA, 
Triton X-100, Tris-base, beparin-agarose,  bovine fibronectin, soybean tryp- 
sin inhibitor, porcine intestinal beparin, and casein from Sigma Chemical 
Co.  (St.  Louis,  MO);  CNBr-activated  Sephamse  4B  and  protein  A 
Sepharose 4B from Pharmacia Fine Chemicals (Piscataway, NJ); Tween-80 
from J. T. Baker Chemical Co. (Phiilipshnrg, NJ); L-35S methionine (1,100 
Ci/mmol), 125I-labeled  donkey anti-rabbit IgG, and carrier-free 125I (12.5 
mCi/t~g) from Amersbam Corp.  (Arlington Heights,  IL); nitrocellulose 
sheets from Schleicher & Schnell, Inc. (Keene, NH); iodobeads from Pierce 
Chemical  Co.  (RocLford,  IL);  reagents  for  SDS-PAGE  from  Bio-Rad 
Laboratories (Richmond, CA); XAR-5 x-ray film from Eastman Kodak Co. 
(Rochester,  NY); prestained high molecular weight standard protein mix- 
ture from Bethesda Research  Laboratories (Gaithersburg, MD).  Bovine 
PAI-1 was purified from BAE CM as described (Hekman and Loskutoff, 
1988) using standard chromatographic techniques in the absence of SDS. 
Analysis of the final preparation by SDS-PAGE and staining with silver 
(Morrissey,  1981) revealed  a  single protein of Mr 50000.  Activation  of 
purified PAI-1 with 4  M guanidine hydrochloride was performed as de- 
scribed (Hekman and Loskutoff,  1985).  Bovine Vn was  purified from 
pooled bovine plasma as described (Yatohgo et al.,  1988). Analysis of the 
final preparation by SDS-PAGE under reducing conditions and staining with 
silver revealed two polypeptides  of Mr 80,000 and Mr 65,000. Radioiodina- 
tion of Vn was performed with 125-indine  and iodobends  according to the 
manufacturer (Pierce Chemical Co.). Antiserum to bovine Vn was raised 
in rabbits, and the IgG fraction was further purified by affinity chromatogra- 
phy on immobilized Vn using standard procedures  (Harlow  and Lane, 
1988). Laminin, type IV collagen,  and matrigel  were generous gifts from 
Dr. J. Madri (Yale University, New Haven, CT). Rabbit antihuman Vn was 
kindly provided  by Drs.  J.  Smith and D.  Cheresh (Research  Institute of 
Scripps  Clinic,  La Jolla, CA). 
Cell Culture 
BAEs were isolated  from bovine aortae and cloned from a single factor 
VIII-positive cell as described (van Mourik et al., 1984). Cells were grown 
to confluence in MEM containing 10% calf serum on either 150-mm cul- 
ture plates or 75 cm  2 flasks and maintained at confluence (105 ceils/cm  2) 
for 3 d before use unless otherwise specified.  Human umbilical vein en- 
dothelial cells (HUVECs) were isolated from freshly collected umbilical 
cords as described (Schleef et al.,  1988).  HT  1080 cells were grown in 
DME with 10% FCS, while HEP 3B ceils were cultured in DME; FI2 with 
10% FCS.  HUVEC, HT 1080, and HEP 3B were grown to confluency in 
6-well culture plates (9.4 cm2). 
Preparation of ECM 
The term ECM as employed here refers to the ECM-substratum-attached 
proteins.  It thus consists of ceil-derived ECM proteins and absorbed serum 
proteins.  It was prepared as described (Mimuro et al.,  1987). Briefly, the 
cells were removed from the culture plate by extraction into 0.5% Triton 
X-100. The extracts were discarded, and the ECM remaining on the culture 
dish was washed three times with PBS and then extracted into 0.1% SDS. 
A serum-derived matrix fraction was obtained by incubating empty 150- 
mm culture plates with MEM containing 10% calf serum at 37°C for simi- 
lar times as the cells grown for ECM preparation. The plates were then 
washed three times with PBS, and the serum-derived matrix fraction was 
prepared as for ECM by extraction with 0.5% Triton X-100, and then with 
0.1% SDS. In other experiments, culture dishes were coated with purified 
Vn, Fn, laminin, type IV collagen, matrigel (Kleinman et ai., 1986), or se- 
rum. Briefly, 6-well dishes (9.4 cm  2) were incubated overnight at 4°C in 
I ml of PBS containing 25 ~g of the purified components, or matrigel, or 
10% serum in MEM. The dishes were washed with PBS, incubated with 
3% BSA in PBS (4°C,  16 h) to block remaining protein binding sites, and 
washed again. This procedure has been reported to promote the saaLrahle 
and reproducible binding of matrix components to tissue culture dishes 
(Form et ai.,  1986). 
Metabolic Labeling of Cells 
BAE monolayers  and trypsin released cells were washed two times with 
serum-free MEM and one time with methionine-deficient  MEM. The cells 
were  labeled  for  various  times  with  35S-methionine  (100  ~tCi/ml)  in 
methionine-deflcient  MEM and then CM, cell extract and ECM were pre- 
pared as above and analyzed as described. For pulse-chase experiments, the 
washed monolayers  were  exposed  to 35S-methionine for only  1 h, then 
washed and chased in serum-free MEM for up to 24 h. In some experi- 
ments, BAEs were labeled during the attachment and spreading process.  In 
these experiments,  the confluent monolayer was removed with trypsin and 
the trypsin was neutralized with soybean trypsin inhibitor (500 ~tg/ml). Af- 
ter  washing,  the  cells  were  plated  at  confluence  (105 cellgtcm  2)  in 
methionine-deflcient  MEM containing 3SS-methionine (100/~Ci/rul).  After 
6 h, the CM, cell extract, and ECM were prepared and analyzed.  The label- 
ing medium for HUVEC cultures also was supplemented with endothelial 
cell growth factor (75 ~g/ml). 
Immunoprecipitation Analysis 
Metabolically labeled cellular samples were mixed with an equal volume 
of immunoprecipitation buffer (PBS containing casein [1%], aprotinin [10 
U/ml], benzamidine hydrochloride [10 mM], and Triton X-100 [0.1%]) and 
antibodies were  added  (i.e.,  polyclonai  antiserum [3%  vol/vol]  raised 
against bovine PAL1 [van Mourik et al., 1984]; affinity-purified anti-bovine 
Vn IgG [10 ~g/ml]; rabbit antihuman Vn [3% vol/vol]).  The samples were 
rocked overnight at 4°C, and then incubated for 2 h at room temperature 
with protein A  Sepharose.  Nonbound proteins were  removed  from the 
Sepharose beads by sequential  washing with immunoprecipitation buffer, 
2 M NaCI containing 0.1% Triton X-100, and finally with distilled water. 
Bound proteins were released  from the beads by boiling in sample buffer 
(in the case of Vn, the SDS contained 50 mM DTT) and fractionated by 
SDS-PAGE. After electrophoresis,  the gels were soaked in Amplify, dried, 
and exposed to Kodak XAR-5 x-ray film with intensifying screens. In some 
experiments,  the autoradiogram was used to localize PAI4 in the gel. These 
regions were  excised,  h~rolyzed,  and  subjected to  liquid scintillation 
counting. 
Ligand Binding Assay 
A ligand  binding assay to detect PALl  binding proteins was performed. 
Briefly, samples were fractioned by SDS-PAGE and the proteins in the gel 
transferred to nitrocellulose (Towbin et al., 1979). The nitrocellulose sheets 
were incubated with guanidine-reactivated  PAI-1 (0.25 riM) for 16 h (4°C) 
and washed. Bound PALl was detected by incubating the sheets with rabbit 
anti-PAI-1 IgG (van Mourik et ai.,  1984) followed by 125I-labeled donkey 
anti-rabbit IgG. After washing,  the nitrocellulose sheets were exposed to 
Kodak XAR-5  x-ray film. 
lmmunoblotting 
Samples were fractionated by SDS-PAGE and transferred to nitrocellulose 
(Towbin et ai., 1979). The nitrocellulose sheet was soaked in PBS contain- 
ing 1% casein (PBS/casein) for 1 h at room temperature to block additional 
protein binding sites and then incubated at room temperature for 2 h with 
affinity-purified  anti-Vn IgG (1  /tg/ml in PBS/casein).  The nitrocellulose 
sheet was washed three times with PBS/casein and then incubated for 2 h 
at 22°C with 125I-labeled donkey anti-rabbit IgG (200,000 cpm/ml). The 
nitrocellulose sheet was washed, dried, and autoradiograms were prepared 
by using Kodak MAR-5 x-ray film. 
Miscellaneous 
SDS-PAGE was performed on slab gels  according to the procedure de- 
scribed by Laemmli (1970).  The upper stacking gel contained 4% acryl- 
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protein concentration  was determined  by the method of Bradford (1976) 
using rabbit IgG as a standard protein for IgG and BSA for all other pro- 
teins. The protein  concentration  of  laminin and type  IV collagen  was deter- 
mined by enzyme  immunoassay  (Form  et al., 1986). Molecular  mass mark- 
ers included  carbonic  anhydrase  (Mr 29,000), ovalbumin  (Mr 43,000), BSA 
(Mr 68,000), and phosphorylase  b (Mr 97,000). 
Results 
Identification of  PAI-1 Binding Proteins in the ECM 
We showed previously that PAI-1 could bind to the ECM of 
cultured BAEs (Mimuro et al., 1987) and that bovine plasma 
contained a protein that also bound to PAL1 and prevented 
its interaction with ECM (Mimuro and Loskutoff, 1989a). 
Although the plasma protein was shown to be Vn, no attempt 
was made in those experiments to establish the identity and 
source of the PAL1  binding protein(s) in the ECM  itself. 
Thus, experiments were performed to characterize the PAI-1 
binding protein(s) present in the ECM (Fig.  1). Purified Vn 
was used as a standard for these studies. The Vn contained 
two polypeptides of Mr of 80,000 and 65,000 (Fig.  1 A, lane 
/), and both of these were positive when tested in the PAL1 
ligand binding assay (Fig.  1 B, lane/). The ECM contained 
two major polypeptides (Mr 63,000 and 57,000) and a mi- 
nor polypeptide (Mr 80,000),  all of which bound to PAL1 
(Fig. 1 B, lane 2). Similar results were obtained if ECM was 
prepared from cells removed with EDTA instead of Triton 
X-100, thus minimizing the possibility that cytoskeletal pro- 
teins (Fey et al., 1980) or absorbed cellular debris remained 
in the ECM fraction (not shown). All of these polypeptides 
also were recognized by antibodies to Vn (Fig.  1 A, lane 2), 
suggesting that they are a mixture of native (80 kD) and par- 
tiaily degraded Vn. The 45-50 kD protein seen in Fig. 1 B, 
lane 2  is the endogenous PAL1 present in ECM (Fig.  1 B, 
compare lanes 2 and 4). Most of the Vn-related material in 
the ECM  has a  lower Mr than the purified Vn  (Fig.  1 A, 
compare lanes  1  and 2)  and probably represents partially 
degraded Vn. 
Origin of PAI-1 Binding Proteins in the ECM 
The detection of significant amounts of Vn in the ECM (Fig. 
1), together with the observation that serum Vn absorbs to 
plastic and promotes cell spreading (Holmes, 1967), raised 
the possibility that the binding of PAI-1 to ECM was medi- 
ated,  at  least in  part,  by serum-derived Vn.  Experiments 
were performed to access this possibility (Fig.  2).  Serum 
was adsorbed to plastic tissue culture dishes, the dishes were 
washed,  and  the  "serum-derived matrices" were prepared 
using the same procedures employed for the preparation of 
cell-derived ECM (see Materials and Methods). The serum- 
derived  matrices  were  then  analyzed by  immunoblotting 
with antibodies to Vn (Fig. 2 A) and by ligand blotting (Fig. 
2 B). The PAId binding pattern for this serum-derived ma- 
Figure 1.  Detection of PAI-1 
binding-proteins in the ECM. 
Puritied Vn and ECM prepared 
as described under Materials 
and Methods, were chemical- 
ly reduced (50 mM dithioery- 
threitol), and then fractionated 
by SDS-PAGE and transferred 
to nitrocellulose.  (A) The mem- 
brane was analyzed by immu- 
noblotting  by  using  affinity- 
purified anti-Vn IgG followed 
by  t2SI-labeled donkey  anti- 
rabbit IgG, and  subjected to 
autoradiography. (lane 1) Pu- 
rified Vn (500  ng);  (lane 2) 
ECM  (equivalent to 25  cm  2 
area of culture dish). (B) The 
nitrocellulose sheets were ana- 
lyzed  by  ligand  blotting  by 
sequentially incubating them 
with activated  PAI-1 (0.25 riM), 
followed by rabbit anti-PAI-I 
antiserum, and then with mI- 
labeled  donkey  anti-rabbit 
IgG. The washed nitrocellu- 
lose sheets then were subjected 
to  analysis by  autoradiogra- 
phy.  Controls  were  treated 
identically,  except  that  the 
PAI-1  incubation  step  was 
omitted. (Lane 1) Purified Vn 
(500 ng); (lane  2) ECM (equiv- 
alent to 25 cm2); (lane 3) Vn 
cont~l; (lane 4) ECM control. 
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binding-proteins in the ECM. 
Bovine serum and the serum- 
derived matrix  fraction were 
prepared  as described  under 
Materials and Methods, frac- 
tionated by  SDS-PAGE, and 
transferred  to  nitrocellulose. 
The  washed  nitrocellulose 
sheets were analyzed by im- 
munoblotting with antibodies 
to  Vn  and  by  PAL1 ligand 
binding. (A) Analysis by im- 
munoblotting; (lane 1) ECM 
(equivalent to 25 cm2); (lane 
2) serum-derived matrix frac- 
tion  (equivalent to 25  cm2); 
(lane 3) serum (0.25 ~1). (B) 
Analysis by PAL1 ligand bind- 
ing; (lane 1) serum-derived  ma- 
trix fraction (equivalent to 25 
cm2); (lane 2) serum (0.5 #1). 
trix fraction (Fig. 2 B, lane/) was very similar to that ob- 
tained from the endothelial cell ECM (Fig.  1 B, lane 2). In 
fact, serum itself contained PAI-1 binding proteins (Fig. 2 B, 
lane 2) which were similar in molecular size to those present 
both in the ECM (Fig. 1 B, lane 2) and in the serum-derived 
matrix fraction (Fig. 2 B, lane/). Again, both of these pep- 
tides were immunologicaUy related to Vn (Fig. 2 A, lanes 2 
and 3). The Mr 50,000 polypeptide (i.e., PAL1) observed in 
the ECM (Fig. 1 B, lane 2) was missing in the serum-derived 
matrix fraction (Fig.  2  B,  lane/).  Thus,  the PAI-1 in the 
ECM was not serum derived but was produced by the BAEs 
themselves. 
These rather unexpected results indicate that much of the 
Vn in the ECM is serum derived, and raise the possibility 
that BAEs do not produce the Vn to which PAL1 binds. Ex- 
periments were performed to measure Vn biosynthesis by 
these cells. BAEs were cultured in the presence of 35S-methi- 
onine and the resulting CM was subjected to immunoprecip- 
itation by using  antibodies  against  Vn  (Fig.  3).  Purified, 
m25I-labeled Vn was used as a  positive control in these ex- 
periments (Fig. 3, lane/). No radiolabeled Vn was detected 
in immunoprecipitations obtained from CM (800,000 TCA 
precipitable cpm; not shown), cell lysates (3,000,000 cpm; 
not shown), or ECM (120,000 cpm; Fig.  3, lane 2). Exog- 
enously added radiolabeled Vn could be quantitatively im- 
munoprecipitated from the ECM, CM, and cell lysates (not 
shown), indicating that these cellular fractions did not inter- 
fere with the immunoprecipitation reaction. The experiments 
with  ~25I-labeled Vn indicate that the lower detection limit 
for this approach was 0.2 ng Vn. In contrast to these results, 
radiolabeled Vn was readily immunoprecipitated from the 
CM of the human hepatoma cell line, HEP 3B (Fig. 3, lane 
3). In fact, analysis of as little as 1,000 cpm (TCA precipita- 
ble) of the CM from HEP 3B was sufficient to obtain a posi- 
tive signal (data not shown). These results suggest that the 
binding of PAI-1 to the ECM of cultured BAEs is dependent 
on the presence of Vn in the culture serum, and not on Vn 
biosynthesis by the cells themselves. 
Experiments were performed to assess the generality of 
this conclusion. Two human cell lines, HUVECs (Levin and 
Santell, 1987) and HT 1080 cells (Laiho et al.,  1987), also 
were reported to deposit PAI-1 into their ECM. The ability 
of these  cells  to  produce  Vn  was  investigated  as  above. 
Confluent  cultures  were  metabolically  labeled  with  asS- 
methionine for 6 h and the CM, cell lysates, and ECM were 
prepared and immunoprecipitated using antibodies to Vn. 
Again, no radiolabeled Vn was detected in the CM of these 
cells (Fig. 3, lanes 4 and 5) or in cell lysates and ECM pre- 
pared from them (data not shown). The rate of Vn biosynthe- 
sis by HUVEC and HT 1080 cells was at least 100-fold less 
than that of HEP 3B cells.  Thus, the presence of PAI-1 in 
the ECM of HUVECs (Levin and Santell,  1987) and HT- 
1080 cells (Laiho et al.,  1987) also is mediated by serum- 
derived Vn. 
Effect of Various Matrix Proteins on the PericeUular 
Localization of  PAI-1 
The effect of different matrix proteins on the pericellular dis- 
tribution of PAL1 was investigated. Cells were plated on cul- 
ture dishes coated with either Vn or Fn and then metaboli- 
cally labeled during the attachment and spreading process 
(Fig.  4).  A  major protein of M~ 50,000 was detectable in 
The Journal of Cell Biology, Volume  111, 1990  1286 Figure  3. Biosynthesis  of  Vn by BAEs, Hep 3Bs, HUVECs, and HT 
1080 cells. Confluent ceils were metabolically labeled with ~S- 
methionine and the resulting CM and ECM were prepared as de- 
scribed under Materials and Methods. The rad_iolabeled Vn was 
collected by immunoprecipitation  using protein A Sepharose, ana- 
lyzed  by  SDS-PAGE and  autoradiography, and  compared  to 
purified nSMabeled bovine Vn. (lane 1) Purified, ~2~I-labeled  Vn 
(10,000 cpm);  (lane 2)  ~sS-labeled ECM  (equivalent to  1 cruZ; 
120,000 TCA precipitable clam); (lane 3) CM from Hep 3B cells 
(results  from  the  immunoprecipitation of 5,000 cpm  of TCA- 
precipitable protein); (lane 4) CM from HUVECs 000,000 cpm); 
(lane 5) CM from HT 1080 cells (100,000 cpm). 
both the CM and ECM of cells which adhered to Vn (Fig. 
4, lanes 1 and 3), and this protein was shown to be PAI-1 
(Fig. 4, lane 5).  PAI-1 was also present in the CM of cells 
plated on Fn (Fig. 4, lane 2), but was absent from ECM (Fig. 
4, lane 4). The rate of  cell attachment and spreading was re- 
duced when BAEs were plated on laminin or type IV colla- 
gen coated-dishes compared to Vn, Fn, matrigel, or serum- 
coated  tissue  culture  dishes  (not  shown).  However,  no 
significant  differences in the overall rate of  protein synthesis 
by the cells could be demonstrated on the different  substrates 
over this time interval (not shown). 
Additional experiments  were  performed to  more  com- 
pletely characterize the influence of ECM proteins on the 
peficellular deposition of PAI-1, and to assess the specificity 
of PAI-1 binding to Vn (Fig. 5).  Similar amounts of PAI-1 
were detected in the CM (Fig. 5 A) and cell lysates (data not 
shown) when cells were plated on laminin (lane/), type IV 
collagen (lane 2), serum (lane 3), and matrigel (lane 4). As 
expected from the results in Fig. 2, PAIl was deposited into 
the culture substratum when cells were plated on serum- 
coated culture dishes (Fig. 5 B, lane 3). However, no PAI-1 
could be detected in the ECM when the cells were cultured 
on laminin (Fig. 5 B, lane/), type IV collagen (Fig. 5 B, lane 
2), or matrigel (Fig. 5 B, lane 4). Moreover, direct binding 
studies using 3~S-labeled PAIl failed to demonstrate PAI-I 
binding to Fn, type IV collagen, laminin, or matrigel (not 
shown). Matrigel is a matrix preparation containing laminin, 
type IV collagen, entactin, and proteoglycan (Kleinman et 
al.,  1986). 
Influence of Vn and Fa on the Kinetics of  PAl-1 
Accumulation in CM and ECM 
Pulse-chase experiments were performed to investigate the 
influence of matrix composition on the kinetics of PAI-1 
deposition into ECM and appearance in CM (Fig. 6). BAEs 
were plated on Vn- or Fn-coated dishes under serum-free 
conditions with 3sS-methionine  for 1 h (pulse). The mono- 
layers were washed again and then incubated for various times 
in serum-free MEM in the absence of label (chase), and both 
CM and ECM were prepared. The overall rate of  protein bio- 
synthesis by cells plated on Vn or Fn was approximately equal 
as  judged by the amount of  TCA-precipitable radioactivity  in 
each culture (data not shown). Immunoprecipitation experi- 
ments indicated that cells plated on Vn rapidly deposited 
PAI-1 into the ECM but released it into the CM only after 
a lag period of 1-2 h  (Fig. 6 A). In these experiments, the 
binding of radiolabeled PAI-1 to Vn was transient: •50%  of 
the bound PAId disappeared from the ECM within 5 h and 
radiolabeled PAI4 could not be detected in the ECM after 
24 h. The appearance of radiolabeled PAIl in CM occurred 
at approximately the same time as the amount of  PAIl in the 
ECM began to decrease, and the rate of PAIl accumulation 
in the CM was similar to the rate of PAI-1 loss from the 
ECM. These results suggest that the accumulation of PAI-1 
in CM resulted from the release of  PAI-1 from ECM. Similar 
results were obtained when serum was absorbed to the cul- 
ture substratum in place of Vn (data not shown). In contrast 
to these results, when the cells were plated on Fn, no lag 
period was observed.  In this instance, the PAI-1 appeared 
to be synthesized and then rapidly and directly released into 
the culture medium (Fig. 6 B). No PAIl was detectable in the 
ECM over the course of the experiment, consistent with the 
results shown in Fig. 4. 
Discussion 
Although large amounts of biologically active PAI-I  have 
been detected in the ECM derived from a variety of cultured 
cells (Laiho et al.,  1986;  Rheinwald et al.,  1987; Knudsen 
et al.,  1987; Mimuro et al., 1987; Levin and Santell, 1987; 
Pollanen et al., 1987),  the identity of the PAI-1 binding pro- 
tein(s) in ECM remains unclear. PAIl circulates in plasma 
complexed to the adhesive glycoprotein Vn (Wiman et al., 
1988; Declerck et al., 1988), and purified Via competes with 
ECM for binding to PAI-1 (Mimuro and Loskutoff, 1989a). 
These observations have led to the suggestion that PAI-1 in 
ECM is bound to Vn (Mimuro and Loskutoff, 1989a). In this 
report, we confirm this hypothesis by showing that Vn is in- 
deed the major PAI-1 binding protein of ECM (Fig,  1), and 
also extend it by showing that the binding of PAI-1 to Vn is 
fairly specific. The inhibitor was not detected in ECM when 
cells were plated on tissue culture dishes coated with other 
basement membrane proteins (i.e., laminin, Fn, type IV col- 
lagen and matrigel; Figs. 4-6),  and direct binding studies 
failed to demonstrate the binding of  PAM to any of  these ma- 
trix proteins. Thus, while these proteins were able to medi- 
ate the adhesion and spreading of BAEs, they were unable 
to replace Vn in the ECM as PAI-1 binding proteins. 
Vn was also found to influence the relative rate of accumu- 
lation of PAI-1 in ECM and CM. For example, when BAEs 
were plated on Vn, the majority  of  secreted PAIl was rapidly 
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the pericellular deposition of  PAI-1. BAEs were re- 
moved from the culture dish by trypsin, washed, 
and  then plated  on Vn- or Fn-coated  dishes  in 
serum-free  medium  containing  3sS-methionine. 
After 6 h the  CM was collected,  the cells were 
lysed with Triton X-100, and the ECM was pre- 
pared (see Materials  and Methods).  The samples 
were  fractionated  by  SDS-PAGE,  and  the  gels 
were  dried  and  analyzed  by fluorography.  CM 
(lane 1) and ECM (lane 3) from cells plated on 
Vn-coated dishes; CM (lane 2) and ECM (lane 4) 
and from cells plated on Fn-coated dishes. Lane 5 
shows PAI-1 immunoprecipitated  from the CM of 
cells  plated  on Vn-coated dishes  (see  Materials 
and Methods). 
deposited into the ECM but appeared in the CM only after 
a significant lag period (Fig. 6). This behavior is similar to 
that observed previously for PAl-1 secretion by mesothelial 
cells (Rheinwald et al.,  1987) and HT 1080-cells (Laiho et 
al.,  1987), and has raised the possibility that PAl-1 may be 
released in a  polar manner.  However, this apparent polar 
deposition of PAIl was only observed when the ceils were 
plated on Vn (Fig. 6 A). When the cells were cultured on Fn- 
coated culture  dishes,  PAl-1  was  rapidly  and  directly  re- 
leased into the medium, and none was detected in the ECM 
(Fig. 6 B). Thus, the pericellular distribution of PAI-1 actu- 
ally reflects the composition of the ECM itself. 
The observation that three cell types previously reported 
to deposit PAId into their ECM (i.e., BAEs, HUVECs, and 
HT-1080 cells) do not synthesize detectable amounts of Vn 
(Fig. 3), was rather unexpected in view of this requirement 
that Vn be present for PAl-1 deposition into ECM (Fig. 6). 
It now seems clear that the majority of PAI-1 in the ECM of 
Figure 5.  Effect of laminin,  type IV coUa- 
gen, matrigel, and serum on the deposition 
of PAIl in the ECM. Tissue culture dishes 
were coated with laminin (lane 1), type IV 
collagen  (lane  2),  serum  (lane  3),  and 
matrigel (lane 4) as described in Materials 
and Methods.  BAEs were plated on these 
matrixes as in Fig. 4 and labeled with 3~S- 
methionine  under  serum-free  conditions. 
After 6 h, the CM (A) and ECM (B) were 
prepared.  PAI-1 was  isolated  from each 
sample by immunoprecipitation  and  ana- 
lyzed by SDS-PAGE and autoradiography. 
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of PAl-1 from cells and deposition into ECM. 
BAEs were plated on Vn (,4)  or Fn (B) matrixes 
in serum-free media for 24 h, washed, and then 
incubated with  35S-methionine for  1 h.  The 
cultures were washed with serum-free medium 
and then incubated in serum-free medium for 
the indicated times and CM (o) and ECM (o) 
were prepared. The PAl-1 present in each sam- 
ple was collected by immunoprecipitation and 
the  immunoprecipitates  were  analyzed  by 
SDS-PAGE  and fluorography. The radiolabeled 
PAl-1 was excised from the gel and the amount 
of radioactivity present in each sample was de- 
termined by liquid scintillation counting. The 
amount of PAl-l-specific cpm present in the 
CM at the end of the 1-h labeling period also 
was determined by immunoprecipitation. The 
cpm present in these samples were added to the 
PAl-l-specific cpm at each time point and the 
combined cpm are shown in the figure. The in- 
sets show the actual autoradiograms. The data 
shown are representative of three independent 
experiments. 
these cells is bound to Vn adsorbed to the plastic tissue cul- 
ture dish from the growth serum (Figs.  1 and 2). The high 
concentration of Vn in the serum used for cell culture, to- 
gether with the tendency of Vn to adsorb to plastic surfaces 
(Holmes, 1967; Hayman et al.,  1985), raises the possibility 
that serum-derived Vn may be responsible, in large part, for 
the presence of PAI-1 in matrices prepared from other cells 
as  well.  This hypothesis is  supported by immunofiuores- 
cence studies which indicate that matrix-associated PAI-1 ex- 
ists as a "rather homogenous carpet" under cells (Pollanen 
et al.,  1987;  Schleef et al.,  1990). This is the predicted be- 
havior of proteins adsorbed to the plastic substratum, and 
not characteristic of matrix fibrils. We are currently inves- 
tigating the possibility that Hep 3B cells which produce both 
PAI-1 and Vn (Fig. 3) may be able to deposit PAI-1 into the 
ECM in the absence of serum. 
It should be mentioned that there may be some PAI-1 in 
the ECM that is not associated with Vn.  For example, pre- 
liminary examination of cross sections of BAEs by immuno- 
gold EM using antibodies to PAI-1 (Podor and Loskutoff, un- 
published observation) indicates that PAI-1 is distributed in 
two distinct pools in  the ECM.  Although the majority is 
clearly associated with Vn on the culture substratum, a sec- 
ond class of PAI-1 was detected in clusters between fibronec- 
tin fibrils. This second minor class of PAI-1 may be associ- 
ated with another protein, one actually synthesized by the 
cells and deposited into the ECM.  This possibility is cur- 
rently under investigation. 
The generality of the observation that PAI-1 is present in 
the ECM of cultured cells has raised the possibility that PAI-1 
may also be present in the ECM in vivo, and has led to the 
suggestion that cells may deposit PAI-1 into their matrix as 
a specific mechanism to protect protease-sensitive structures 
from cell-  and  plasma-derived  proteinases  (Dano  et  al., 
Seiffert et al.  Type 1 Plasminogen Activator Inhibitor  1289 1985; Laiho et al., 1986; Knudsen et al., 1987). The demon- 
stration that much of this PAI-1 is adsorbed to serum-derived 
Vn would seem to decrease the physiological significance of 
this observation in vivo. In spite of this, Vn has been detected 
in the ECMs of various tissues (Hayman et al.,  1983),  in- 
cluding the vessel wall (Guettier et al.,  1989;  Niculescu et 
al.,  1989).  The unique distribution  of Vn in the vessel wall 
suggests that it is actually produced by vascular  cells. The 
observation that bovine and human endothelial cells do not 
produce Vn (Fig. 3) implies that the Vn in the vessel wall is 
synthesized  by  other  vascular  cells  (e.g.,  smooth  muscle 
cells). Whether PAI-1 is also present in the vessel wall re- 
mains to be investigated.  The actual  site of synthesis of Vn 
in vivo in unclear,  although plasma Vn levels are reduced in 
patients  with liver disease  (Kemkes-Matthes  et al.,  1987) 
suggesting a liver origin. The observation that two hepatoma 
cell lines (Hep 3B; Fig. 3) and Hep G2 (Barnes and Reing, 
1985) produce significant amounts of Vn, supports this idea. 
In summary, these results indicate that the pericellular dis- 
tribution of PAI-1 in cultured cells actually reflects the com- 
position of the ECM itself, and that this composition is, in 
turn,  influenced by serum. According to this hypothesis,  if 
PAL1 binding proteins (i.e., Vn) are present in the ECM but 
not in the culture medium, then newly synthesized PAI-1 will 
bind to them and rapidly accumulate there.  This would be 
the situation for cells cultured initially in complete medium 
and then placed in serum-free medium for various times. 
Many  of the matrix preparations  previously shown to con- 
tain substantial  amounts of PAId (Laiho et al., 1986;  Levin 
and Santell,  1987;  Mimuro et al.,  1987;  Rheinwald et al., 
1987) were in fact prepared from ceils cultured  in this way. 
Since  the  interaction between  Vn  and  PAL1  is  reversible 
(Mimuro et al.,  1987;  Declerk et al.,  1988;  Mimuro and 
Loskutoff,  1989a;  Salonen et al.,  1989; Wun et al.,  1989), 
and since latent  PAL1 has a relatively  low affinity  for Vn 
(Declerk et al., 1988;  Mimuro and Loskutoff, 1989b), latent 
PAI-1 should accumulate in the medium as active PAI-1 is 
spontaneously released from the ECM, and this seems to be 
the case (Fig. 6). It is well known that latent PAI-1 accumu- 
lates in the serum-free conditioned medium of a variety  of 
cells (Hekman and Loskutoff, 1985;  Loskutoffet al., 1989). 
Another prediction from this model is that when cells are 
cultured continuously in the presence of serum, active PAI-1 
will accumulate directly into the medium. In this case, se- 
rum Vn should compete with the Vn in ECM for binding to 
active PAL1 and thus minimize its deposition into ECM. The 
active  PAI-1  in  the  medium  should  then  be  stabilized 
(Mimuro et al., 1987; Declerck et al., 1988) by the high con- 
centrations of Vn present in the serum. Preliminary observa- 
tions indicate that active PAI-1 accumulates in the medium 
of cells cultured  in the presence of serum (Lindahl and Wi- 
man,  1989). 
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